KC-4546

Ba/F3 ERBB2 S310F EGFR Cell Line

47017

Home » Ba/F3 ERBB2 S310F EGFR Cell Line

Background of Ba/F3 ERBB2 S310F EGFR Cell Line

HER2, also named ERBB2, is a cell-surface receptor tyrosine kinase, ERBB2 overexpression or overactivity have associated with a number of cancers, especially the breast cancer. The identification of ERBB2 as a driver gene has led to the development of anticancer therapeutics agents, including lapatinib, Neratinib and Herceptin.
The protein encoded by EGFR is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer.
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.

Specifications

Catalog Number	KC-4546
Cell Line Name	Ba/F3 ERBB2 S310F EGFR Cell Line
Host Cell Line	Ba/F3 ERBB2-S310F
Description	Stable Ba/F3 ERBB2-S310F clone expressing exogenous EGFR gene
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% RPMI1640+20% FBS+10% DMSO
Propagation Medium	RPMI1640+10%FBS+1000µg/mL Hygromycin B
Selection Marker	Puromycin, Hygromycin B
Morphology	Mostly single, round (some polymorph) cells in suspension
Subculture	Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 10⁵ cells/mL
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 20 hours
Mycoplasma Status	Negative

Cell Line Generation

Ba/F3 ERBB2-S310F-EGFR cell line was generated using a lentiviral vector expressing EGFR sequence.

Characterization

Figure 1: Characterization of ERBB2 overexpression in Ba/F3 ERBB2-S310F-EGFR stable clones using FACS.

Figure 2: Characterization of EGFR overexpression in Ba/F3 ERBB2-S310F-EGFR stable clones using FACS.

Figure 3: Characterization of ERBB2-S310F and EGFR expression in Ba/F3 ERBB2-S310F-EGFR stable clones using PCR sequencing.

Cell Resuscitation

Prewarm culture medium (RPMI1640 supplemented with 10% FBS and 1000µg/mL Hygromycin B)in a 37°C water bath.
Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
Incubate the flask at 37°C, 5% CO₂ incubator.
Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 10⁵ cells/mL.

Cell Freezing

Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use.
Keep the freezing medium on ice and label cryovials.
Transfer cells to a sterile, conical centrifuge tube, and count the cells.
Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
Resuspend the cells at a density of at least 3×10⁶ cells/mL in chilled freezing medium.
Aliquot 1 mL of the cell suspension into each cryovial.
Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
Transfer vials to liquid nitrogen for long-term storage.

References

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006 Jul;10(1):25-38. doi: 10.1016/j.ccr.2006.05.023. PMID: 16843263.